Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis

Supported by findings from a large global survey of RMS patients and care partners, vs.MS provides information and tools aimed at driving better informed care –

vs.MS Survey Results (Graphic: Sanofi Genzyme)

CAMBRIDGE, Mass.--()--Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the launch of vs.MS, a global initiative focused on highlighting and addressing the sometimes debilitating symptoms that accompany MS, as well as their daily impact on people living with and affected by the disease.

This World MS Day, Sanofi Genzyme is putting a call out to the MS community to learn more about the real impact of the disease and to declare themselves vs.MS on the campaign website, For each vs.MS declaration, Sanofi Genzyme will make a donation to the Multiple Sclerosis International Federation (MSIF).

To inform the vs.MS campaign, a global survey was fielded among more than 1,500 people living with relapsing MS (RMS) and their care partners in seven countries: Australia, Canada, France, Italy, Spain, the United Kingdom and the United States. Results from the survey reveal the physical and emotional toll that RMS patients face on a day-to-day basis. Additional survey findings are available on the vs.MS website. Some findings include:

  • More than half of respondents living with RMS find that issues with memory limit their daily activities
  • More than half of respondents living with RMS say their ability to process information has slowed down
  • Nearly half of respondents living with RMS feel limited by depression or anxiety
  • More than half of respondents living with RMS feel lonely or isolated because of their RMS
  • Two-thirds of respondents living with RMS say their disease has affected their ability to keep their job
  • More than one-third of respondents feel urinary problems associated with their RMS are a factor in the decisions they make when planning to leave the house
  • More than half of care partner respondents do not discuss their fear of RMS progressing to avoid upsetting the person they care for

As part of our ongoing commitment to improving the lives of people affected by this debilitating disease, we are proud to launch vs.MS,” said Carole Huntsman, Global Multiple Sclerosis Lead, Sanofi Genzyme. “The compelling findings from this survey broaden our understanding of the true cognitive and emotional toll that MS takes, and will help guide our efforts to better partner with the community to meet the overall needs of MS patients.”

To arm the MS community with the tools and resources they need to be vs.MS, the campaign website includes videos, educational modules and survey results highlighting the real burden of the disease.

To learn more about vs.MS and view the survey findings, visit and follow along on social media via the campaign hashtag, #vsMS.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Learn more at

Genzyme® is a registered trademark of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Sanofi Genzyme Media Relations
Erin Walsh, +1 617-768-6881


Sanofi Genzyme Media Relations
Erin Walsh, +1 617-768-6881